DegenRx B.V.
DegenRx is a biotech startup working on AAV-mediated gene therapy for CNS disorders like Parkinson's and Alzheimer's. They transmit genes to the brain that start the local synthesis of therapeutic antibodies using adeno-associated-viral vectors. Its goal is to discover and create treatments for neurodegenerative disorders so people can age longer and healthier.
Industries
Nr. of Employees
small (1-50)
Products
AAV-mediated Gene Therapy for Alzheimer's Disease
A gene therapy approach using AAV vectors to deliver genes encoding for antibodies directly into the brain to treat Alzheimer's disease.
AAV-mediated Gene Therapy for Parkinson's Disease
A gene therapy approach using AAV vectors to deliver genes encoding for antibodies directly into the brain to treat Parkinson's disease.
Gene Therapy Technology
A technique that introduces genetic material into cells using AAV vectors to produce therapeutic proteins, particularly for treating neurodegenerative diseases.
AAV-mediated Gene Therapy for Alzheimer's Disease
A gene therapy approach using AAV vectors to deliver genes encoding for antibodies directly into the brain to treat Alzheimer's disease.
AAV-mediated Gene Therapy for Parkinson's Disease
A gene therapy approach using AAV vectors to deliver genes encoding for antibodies directly into the brain to treat Parkinson's disease.
Gene Therapy Technology
A technique that introduces genetic material into cells using AAV vectors to produce therapeutic proteins, particularly for treating neurodegenerative diseases.